SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pump.fun

Pump.fun is generating intense community engagement as a central hub for memecoin activity on the Solana network, with traders actively debating its dual reputation as a high-volume launchpad and a source of high-risk speculative tokens. Users are currently focused on viral marketing strategies, token accumulation, and the emergence of community-led projects like $PMV and $WAGMI, while navigating discussions around platform transparency and market volatility.

BioLLM

BioLLM is capturing significant social media attention as the project markets itself as the first language model integrated with living cortical neurons. While some community members are actively promoting the token's technological ambition, others are expressing skepticism and warning of potential pump-and-dump dynamics.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The RAGE community is driving momentum for the token by emphasizing its status as an 'original' internet meme, actively restoring historical comic-generation tools to build long-term cultural value. Supporters are rallying around a 'bag-working' culture, urging others to reject fleeting trends in favor of this established IP.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The community is currently fractured, with some retail traders promoting speculative pumps and decentralized community takeovers on the Solana network, while vocal critics are warning others about the history of dilution and alleged scams associated with the brand. Discussion remains polarized as some users chase extreme volatility in low-market-cap tokens, while many others share bitter experiences from past equity losses and dismiss current activity as another cycle of exploitation.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating significant buzz due to its ultra-low circulating supply, which market participants believe creates the perfect conditions for a substantial price surge. The community is actively tracking potential volume spikes and discussing the token's DeFi integration, with many investors pointing to its scarcity as a primary catalyst for potential long-term growth.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is gaining investor attention as it positions its modular power solutions to address the critical electricity bottlenecks facing AI-driven data centers. While the community remains divided over management's execution and the ongoing lack of firm contract announcements, many are watching closely for news on scaling manufacturing and potential deployments tied to the PORTHOS project.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is currently in the spotlight as investors weigh the impact of its strategic reset, including significant write-downs and a suspension of dividends, against promising revenue growth in North American and European markets. The community is actively debating the company's turnaround potential, specifically focusing on its pivot toward traditional powertrain options like V8 engines and new collaborative ventures in the robotaxi and AI space as potential catalysts for long-term recovery.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently navigating high market volatility as traders weigh conflicting geopolitical headlines regarding the Iran conflict against institutional accumulation patterns. The community remains deeply divided, with some actively buying the dip in anticipation of regulatory clarity while others voice concerns over technical vulnerabilities and a potential short-term breakdown in price action.

The Estée Lauder Companies, Inc. engages in the manufacture of skin care, makeup, fragrance and hair care products. It sells products under Estée Lauder, Clinique, Origins, MAC, Bobbi Brown, La Mer, Jo Malone London, Aveda and Too Faced. The company was founded by Estee Lauder and Joseph Lauder in 1946 and is headquartered in New York, NY.

Estee Lauder Cos., Inc. - Ordinary Shares - Class A

Estee Lauder Cos. Inc

Estee Lauder is seeing significant options activity and community debate as investors speculate on a potential turnaround following its recent restructuring and heavy volatility. Traders are actively dissecting the stock's support levels while balancing long-term valuation concerns against the impact of macro headwinds and tariff-related risks.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

The $DOG community is buzzing over reports of a Coinbase listing, which investors view as a major catalyst for increased liquidity and mainstream accessibility. Amidst these developments, the community remains intensely focused on the token's Bitcoin-native structure and decentralized fundamentals, positioning it as a long-term alternative to traditional inflationary memecoins.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Small-Cap Trade Shows Signs Of Life: Investors Add $1.7 Billion To IWM In One Day

iShares Russell 2000 ETF saw $1.7 billion inflow on April 1. This suggests growing interest after a volatile period, but not a full shift in leadership yet.read more...

Best-Performing Leveraged ETFs of March 

War-driven volatility crushed global markets in March, but leveraged ETFs surged. Oil, VIX, and inverse plays dominated the winners' list.



<ul class="summary-bullets"><li>Q4 revenue also fell well short of $555.4 million average revenue projection by the analysts.&nbsp;</li><li>PLAY expects to deliver an increase in same store sales, revenue, adjusted core profit and to generate more than $100 million in free cash flow.</li><li>The company opened two new stores in the fourth quarter for a total of 11 new stores in fiscal 2025.</li></ul>Dave &amp; Buster’s (PLAY) shares garnered investors’ attention and fell 3% during Tuesday’s extended hours of trading as it reported lower fourth quarter revenue.&nbsp;PLAY’s Q4 revenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024. It also fell well short of $555.4 million average revenue projection by the analysts.&nbsp;It also swung to loss during Q4 as it reported adjusted net loss of $12.0 million, or $0.35 per diluted share, compared with an adjusted net income of $25.3 million, or $0.66 per diluted share in the fourth quarter of fiscal 2024.The company opened two new stores in the fourth quarter for a total of 11 new stores in fiscal 2025. PLAY said that it also remodeled 16 Dave &amp; Buster’s stores in fiscal 2025, bringing the grand total to 51 recently remodeled Dave &amp; Buster’s stores since this remodel program began in the second half of fiscal 2023.It also ended the fourth quarter of fiscal 2025 with $482.9 million of liquidity, which included $16.6 million in cash and $466.3 million available under its $650.0 million revolving credit facility, net of letters of credit.&nbsp;<h2 class="st-heading-2">Outlook</h2>PLAY expects to deliver an increase in same store sales, revenue, adjusted core profit and to generate more than $100 million in free cash flow.“In 2026, we will make meaningful improvements to the business, sharpening our marketing to drive brand consideration, refining our pricing and menu architecture, launching a powerful lineup of culturally relevant new games, and implementing our refreshed remodel program,” said Tarun Lal, Chief Executive Officer.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around PLAY stock trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen almost 34% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail sentiment around PLAY stock trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume. 

Dave & Buster’s Stock Falls 3% After Q4 Earnings Miss

 PLAY’s Q4 revenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024.

Equity

PLAY’s Q4 revenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024.


<ul class="summary-bullets"><li>The&nbsp;company&nbsp;opened nine new stores and closed five stores during fiscal 2025.</li><li>JILL said that for the first quarter of fiscal 2026, the company expects its net sales to decline 5% to 7% compared to fiscal 2025.</li><li>Jefferies lowered the firm's price target on J.Jill to $14 from $18 and kept a ‘Buy’ rating on the shares.</li></ul>Shares of J. Jill (JILL) slumped 26% on Tuesday after it reported a 3.1% decline in its fourth quarter net sales.&nbsp;Net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million compared to $142.8 million for the fourth quarter of fiscal 2024, it said. Analysts expected revenue of $135.5 million as per data from Stocktwits.&nbsp;JILL reported adjusted net loss per diluted share in the fourth quarter of fiscal 2025 at $0.02 compared to adjusted net income per diluted share of $0.32 in the fourth quarter of fiscal 2024.The company opened nine new stores and closed five stores during fiscal 2025, ending the year with 256 stores compared to 252 stores at the end of fiscal 2024.<h2 class="st-heading-2">Analyst Rationale</h2>Jefferies lowered the firm's price target on J.Jill to $14 from $18 and kept a ‘Buy’ rating on the shares following the company’s earnings report. The analyst told investors in a note that J.Jill delivered Q4 results "above a low bar," but "more importantly" FY26 guidance came in well below Street expectations, driven by cautious demand assumptions and incremental tariff headwinds.BTIG analyst Janine Stichter lowered the firm's price target on J.Jill to $18 from $21 and kept a ‘Buy’ rating on the shares.<h2 class="st-heading-2">Outlook</h2>JILL said that for the first quarter of fiscal 2026, the company expects its net sales to decline 5% to 7% compared to fiscal 2025. Analysts expected revenue for the quarter at $155.65 million, as per Stocktwits.&nbsp;For the full year of fiscal 2026, the company expects net sales to be flat to down 2% compared to fiscal 2025.JILL said that the outlook assumes an average 20% reciprocal tariff rate on applicable inventory received prior to February 28, 2026, an average 10% reciprocal tariff rate on applicable inventory received after February 28, 2026 through the first quarter of fiscal 2026, and an average 15% reciprocal tariff rate thereafter.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around JILL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company are down 19% so far in 2026.&nbsp;&nbsp;

BTIG analyst Janine Stichter lowered the firm's price target on J.Jill to $18 from $21 and kept a ‘Buy’ rating on the shares.

J. Jill Stock Slumps 26% Today – Why Such A Selloff?

JILL’s net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million year-over-year. 

<ul class="summary-bullets"><li>BlackSky stated that this contract is aimed at helping with the design and development of next-generation space intelligence.</li><li>CEO Brian O’Toole noted that these developments will enable ultra-high-resolution imaging, enhanced collection performance, and low-latency space-based communications.</li><li>BlackSky said the satellites will serve multiple roles, including acting as data storage and processing hubs and integrating with on-orbit data centers.</li></ul>BlackSky Technology Inc. (BKSY) on Tuesday announced that it has won a U.S. government contract for designing technology for Earth observation.The company stated that the contract’s value is $99 million, slightly lower than BlackSky’s full-year 2025 revenue of $107 million. BlackSky also added that it has already received an initial payment of $2 million.<a href="https://stocktwits.com/symbol/BKSY">BlackSky shares</a> were up nearly 9% in Tuesday morning’s trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">Developing Next-Gen Space Intelligence</h2>BlackSky stated that this contract is aimed at helping with the design and development of next-generation space intelligence. It added that the capabilities and mission applications this project addresses are distinct from those addressed by current Gen-2 and Gen-3 monitoring systems and the company’s future AROS broad-area search system.“We will leverage the unique, highly scalable core technology of Gen-3 into every incremental advancement along our roadmap, looking at the AROS broad area search system as the next step into the more expansive very large-aperture optical imagery capabilities covered by this contract,” said BlackSky CEO Brian O’Toole.He added that these developments will enable ultra-high-resolution imaging, enhanced collection performance, and low-latency space-based communications.The company expects the contract to enable expanded applications in high-cadence Earth monitoring and tracking objects across low Earth, geostationary, and cis-lunar orbits.<h2 class="st-heading-2">Satellites With Multi-Role Capabilities</h2>BlackSky noted that the satellites that will be developed under this contract will serve multiple roles. This includes operating as a data storage and processing hub and being compatible with on-orbit data centers.The company noted that this is an indefinite-delivery, indefinite-quantity contract for a multi-year period.BlackSky is a Herndon, Virginia-based company that provides real-time space intelligence with on-demand imagery, analytics, and high-frequency monitoring of critical global assets and events.<a href="https://stocktwits.com/symbol/BKSY">BKSY stock</a> is up 24% year-to-date and 202% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 15% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 22%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warren-buffett-sold-apple-shares-too-soon-berkshire/cZEPvVFRIVi">Buffett Says He Sold Apple Shares Too Soon, But Does Not Regret It: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BlackSky Technology logo is seen displayed on a smartphone screen.

BKSY Stock Is Rising Today – This Government Deal Could Be A Turning Point

BlackSky Technology (BKSY) stated that the contract’s value is $99 million, slightly lower than BlackSky’s full-year 2025 revenue of $107 million.

The company stated that the contract’s value is $99 million, slightly lower than BlackSky’s full-year 2025 revenue of $107 million.

<ul class="summary-bullets"><li>In connection with the transaction, Repay has received a debt commitment letter from Truist Bank for a $500 million term loan, along with a $100 million undrawn revolving credit facility.&nbsp;</li><li>RPAY expects the transaction to close in the second quarter of 2026.</li><li>It expects the transaction to unlock additional value with expected revenue opportunities of approximately $5+ million by 2028.</li></ul>Repay Holdings (RPAY), a provider of integrated payment processing solutions, on Monday announced a definitive agreement to acquire Kubra Data Transfer for approximately $372 million in an all-cash transaction.&nbsp;The company said that the acquisition will be financed with a combination of cash on hand and debt financing.Shares in the company fell nearly 1% during extended hours of trading on Monday.&nbsp;<h2 class="st-heading-2">More Details</h2>In connection with the transaction, RPAY has received a debt commitment letter from Truist Bank for a $500 million term loan, along with a $100 million undrawn revolving credit facility.&nbsp;Repay said that the deal is expected to generate approximately $15+ million of annual run-rate costs synergies and approximately $5+ million of technology savings over the next three years through combining operations, platform consolidation, and other scale efficiencies.&nbsp;“Today’s announcement advances REPAY on our transformational journey to become a leading bill payment provider. The combination brings together highly complementary go-to-market approaches, creating robust opportunities to enhance growth,” said John Morris, Co-Founder and Chief Executive Officer of Repay.The transaction is subject to regulatory approvals in the U.S. and Canada and certain customary closing conditions. The company expects the transaction to close in the second quarter of 2026.<h2 class="st-heading-2">Expected Gains</h2>Repay expects the transaction to unlock additional value with expected revenue opportunities of approximately $5+ million by 2028 as RPAY benefits from offering bill presentment, communications services, a payment engine, and core processing solutions across all clients.It also expects free cash flow accretion of 25% by 2028.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around RPAY stock trended in ‘neutral’ territory amid ‘normal’ message volume.&nbsp;Shares in the company have fallen around 15% so far this year.

Retail sentiment around RPAY stock trended in ‘neutral’ territory amid ‘normal’ message volume. 

Repay Stock Falls As $372M Deal Fails To Impress Investors

The company said that the acquisition will be financed with a combination of cash on hand and debt financing.

<ul class="summary-bullets"><li>Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC&nbsp;reported, citing data from Argus.&nbsp;</li><li>Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28.</li></ul>JetBlue Airways (JBLU) is reportedly raising bag fees for its flyers as rising fuel prices due to the ongoing Iran war begin to&nbsp;weigh on the company.“As we experience rising operating costs, we regularly evaluate how to manage those costs while keeping base fares competitive and continuing to invest in the experience our customers value,” JetBlue said in a statement to CNBC.Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC reported, citing data from Argus.&nbsp;Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28. The recent rise in checked bag fees is the latest indication that airlines are passing higher fuel costs onto American travelers. After labor, jet fuel is the largest expense for airlines.<h2 class="st-heading-2">Rising Fuel Prices&nbsp;</h2>Crude oil jumped on Monday and stayed well above $100 a barrel mark, signalling a prolonged Iran war.&nbsp;Benchmark U.S. oil futures gained $3.24 a barrel Monday to settle at $102.88, their first close above $100 since 2022 when Russia invaded Ukraine and rattled energy markets, as per Wall Street Journal.&nbsp; Brent crude futures for May delivery were as high as $116 Monday.&nbsp;The United States Oil Fund ETF (USO) closed 4.5% higher on Monday, while the ProShares Ultra Bloomberg Crude Oil ETF (UCO) ended the day 1.7% higher.&nbsp;<h2 class="st-heading-2">Retail reaction</h2>Retail sentiment around JBLU&nbsp;stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen around 10% so far this year.&nbsp;

JetBlue Airbus A321neo passenger aircraft spotted departing from the runway of Amsterdam Schiphol Airport in the Netherlands on April 10, 2025.

JetBlue Airways Reportedly Raises Baggage Fees As Rising Fuel Costs Bite

 As JetBlue experiences rising operating costs, it regularly evaluates how to manage those costs while keeping base fares competitive, the airline told CNBC in a statement. 

<ul class="summary-bullets"><li>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging.</li><li>The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.</li><li>Viridian stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter of 2026.</li></ul>Viridian Therapeutics Inc. (VRDN) shares tanked more than 41% in Monday’s pre-market trade after the company announced results from its Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease.Viridian stated that the REVEAL-1 trial of Elegrobart met its primary endpoint of proptosis responder rate (PRR) with a highly statistically significant treatment effect in the four-week dosing regimen.However, the company stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/VRDN">Viridian Therapeutics</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Did The Trial Reveal?</h2>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging. The study also tested a different dosing schedule (every 8 weeks) versus placebo and examined other important outcomes.The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.However, Elegrobart showed only a slight improvement over placebo in the Clinical Activity Score (CAS), a measure of inflammation and disease activity.Viridian’s results showed that the CAS reduction to 0 or 1 was 57% in the four-week regimen and 69% in the eight-week regimen, compared with 50% in the placebo group.The company said that all complaints of adverse events in both regimens were reports of tinnitus, none of which were associated with hearing reduction.<h2 class="st-heading-2">Viridian Says Elegrobart On Track For BLA Submission In 2027</h2>The company stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter (Q2) of 2026.Following this, Viridian plans to submit a Biologics License Application (BLA) to the U.S. FDA in Q1 2027. A BLA is a formal request submitted to the U.S. Food and Drug Administration (FDA) asking for approval to sell a biologic drug.<a href="https://stocktwits.com/symbol/VRDN">VRDN stock</a> is down 12% year-to-date, but up 87% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 40% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 19%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/roma-stock-soars-100m-share-repurchase-program/cZERVIhRIZs">ROMA Stock Shot Up 10% Today – Everything To Know About Its Gigantic Share Repurchase Program</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal?

Viridian stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.

<ul class="summary-bullets"><li>Tonix is now evaluating its Tonmya drug for the treatment of major depressive disorder and acute stress disorder/acute stress reaction.&nbsp;</li><li>The company also expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease.</li><li>According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’.</li></ul>Shares of Tonix Pharmaceuticals (TNXP) fell for the fourth consecutive day on Friday but stayed on the radar of retail investors on Stocktwits who gauged the company’s drug pipeline.Retail chatter around the stock rose 92% over the past 24 hours. Overall, retail sentiment around the stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A user said that the company should cut spending and focus resources on expanding the indication for the company’s FDA-approved drug Tonmya.<stembedurl>https://www.stocktwits.com/ByBi/message/648804308</stembedurl>Another user voiced optimism for the company’s Tonmya drug but noted that the stock is “super diluted.”<stembedurl>https://www.stocktwits.com/BlakeCanyon50/message/648764035</stembedurl>Yet another user voiced optimism for good news while adding that they think it is “very close.”<stembedurl>https://www.stocktwits.com/pickles14/message/648794046</stembedurl><h2 class="st-heading-2">Drug Approvals</h2>The U.S. Food and Drug Administration approved Tonix’s Tonmya for the management of fibromyalgia in adults in August. The non-opioid drug launched in November and through Feb. 27, more than 1,500 healthcare providers prescribed it to patients. About 2,500 patients have initiated treatment with Tonmya, the company said earlier this month.The company is now evaluating the potential of the drug in treating major depressive disorder and acute stress disorder/acute stress reaction.<h2 class="st-heading-2">Other Pipeline Updates</h2>Tonix expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease. There are no FDA-approved vaccines or prophylactics for the disease now.Other candidates in its pipeline include TNX-2900 for the treatment of Prader-Willi syndrome, TNX-1500 for the prevention of kidney transplant rejection, and TNX-1900 for the treatment of migraines.According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’. The 12-month average price target on the stock is $54.33, representing a potential upside of about 322%.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> has dropped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff

On Stocktwits, retail chatter around the stock rose 92% over the past 24 hours as users contemplated on the company’s approved drugs and investigational therapy candidates. 

<ul class="summary-bullets"><li>The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval.</li><li>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company.</li><li>LifeSci Capital added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval.</li></ul>&nbsp;Shares of Rocket Pharmaceuticals Inc. (RCKT) dropped 22% on Friday after the company announced U.S. Food and Drug Administration's approval for its drug in the treatment of an inherited pediatric disorder, a sell-off that Wall Street dismissed as unjustified.Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with severe leukocyte adhesion deficiency-I, an ultra-rare, inherited pediatric immunodeficiency characterized by recurrent, severe infections.The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval. The voucher is designed to encourage the development of therapies for rare pediatric disease<h2 class="st-heading-2">Wall Street Weighs In</h2>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company, which the firm believes reflects management's strong execution. Payer coverage should not be an issue, and the priority review voucher will strengthen Rocket's balance sheet, the analyst told investors in a research note. The firm added that it does not see the negative stock price reaction as justified.LifeSci Capital analyst Patrick Dolezal also reiterated an ‘Outperform’ rating and $9 price target on Rocket Pharmaceuticals. The firm said the PRV could be a potentially meaningful source of non-dilutive capital that could net Rocket $100 million to $200 million. The firm added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval and expects read-through to the company's cardiac gene-therapy pipeline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around RCKT stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/RCKT">RCKT stock</a> has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-model-y-3-deliveries-critical-as-model-s-x-approach-retirement-says-analyst/cZ3HJsGRIm9">Watch Tesla Model Y/3 Q1 Delivery Numbers Closely — Analyst Warns As S/X Near End Of Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with an ultra-rare immune disorder.

iShares Trust - iShares Russell 2000 ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Stocktwits

Stocktwits Polls

iShares Russell 2000 ETF

Traders are closely monitoring escalating Iran-U.S. tensions and potential ground operations, as market sentiment swings wildly on diplomatic news.

Community discussions are heavily focused on identifying horizontal support and resistance levels to play potential market reversals.

Seasoned traders emphasize technical discipline and emotional mastery while mocking less experienced 'gurus' and internet noise.

Investors are expressing deep skepticism over the latest relief rallies, suspecting the current market structure is merely setting up for a rug pull.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWM News

IWMiShares Russell 2000 ETF